LGALS9 and glioblastoma: In our previous studies, TDEVs from GBM patients were found to have the unique protein ligand LGALS9, which inhibits antigen recognition, processing and presentation by dendritic cells (DCs), leading to failure of the cytotoxic T cell-mediated antitumour immune response [7].